NCT05179265View on ClinicalTrials.gov

Recombinant Human Serum Albumin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

July 7, 2022

Study Completion Date

July 7, 2022

Conditions
Hepatic Ascites
Interventions
DRUG

recombinant human serum albumin

10 g/bottle (20%, 50 mL)

DRUG

Human serum albumin

10 g/bottle (20%, 50 mL)

Trial Locations (1)

100084

Shenzheng Protgen Ltd, Guangdong

All Listed Sponsors
lead

Protgen Ltd

INDUSTRY

NCT05179265 - Recombinant Human Serum Albumin in Healthy Subjects | Biotech Hunter | Biotech Hunter